78 related articles for article (PubMed ID: 18800614)
1. [New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].
Shiotsu Y
Rinsho Ketsueki; 2008 Aug; 49(8):641-9. PubMed ID: 18800614
[No Abstract] [Full Text] [Related]
2. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
3. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
4. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
5. FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.
Katsumi A; Kiyoi H; Abe A; Tanizaki R; Iwasaki T; Kobayashi M; Matsushita T; Kaibuchi K; Senga T; Kojima T; Kohno T; Hamaguchi M; Naoe T
Eur J Haematol; 2011 Mar; 86(3):191-8. PubMed ID: 21114537
[TBL] [Abstract][Full Text] [Related]
6. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
7. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
Bavetsias V; Crumpler S; Sun C; Avery S; Atrash B; Faisal A; Moore AS; Kosmopoulou M; Brown N; Sheldrake PW; Bush K; Henley A; Box G; Valenti M; de Haven Brandon A; Raynaud FI; Workman P; Eccles SA; Bayliss R; Linardopoulos S; Blagg J
J Med Chem; 2012 Oct; 55(20):8721-34. PubMed ID: 23043539
[TBL] [Abstract][Full Text] [Related]
8. Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT; Levis M
Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
[TBL] [Abstract][Full Text] [Related]
9. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
10. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
Schroeder T; Zohren F; Saure C; Bruns I; Czibere A; Safaian NN; Fenk R; Haas R; Kobbe G
Acta Haematol; 2010; 124(3):153-9. PubMed ID: 20938170
[No Abstract] [Full Text] [Related]
12. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
Muranyi AL; Dedhar S; Hogge DE
Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
[TBL] [Abstract][Full Text] [Related]
13. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.
Muranyi AL; Dedhar S; Hogge DE
Leuk Res; 2010 Oct; 34(10):1358-65. PubMed ID: 20193963
[TBL] [Abstract][Full Text] [Related]
14. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
15. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Shabbir M; Stuart R
Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
[TBL] [Abstract][Full Text] [Related]
16. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Fesler MJ; Richart JM; Petruska PJ
Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
[No Abstract] [Full Text] [Related]
17. A substrate peptide for the FLT3 receptor tyrosine kinase.
Böhmer FD; Uecker A
Br J Haematol; 2009 Jan; 144(1):127-30. PubMed ID: 19016738
[TBL] [Abstract][Full Text] [Related]
18. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Youssoufian H; Rowinsky EK; Tonra J; Li Y
Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
[TBL] [Abstract][Full Text] [Related]
19. [Application of novel tyrosine-kinase inhibitors for the treatment of leukemia and Ph-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2011 Jul; 52(7):460-8. PubMed ID: 21821977
[No Abstract] [Full Text] [Related]
20. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
